Online citations, reference lists, and bibliographies.

Day-to-Day Impact Of Vaginal Aging Questionnaire: A Multidimensional Measure Of The Impact Of Vaginal Symptoms On Functioning And Well-being In Postmenopausal Women

A. Huang, S. Gregorich, M. Kuppermann, Sanae Nakagawa, S. K. Van Den Eeden, J. Brown, H. Richter, L. Walter, D. Thom, A. Stewart
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ObjectiveThis study aims to develop a self-report questionnaire assessing the impact of vaginal dryness, soreness, itching, irritation, and pain on functioning and well-being in postmenopausal women. MethodsStructured self-report items were developed to address the impact of vaginal symptoms on functioning and well-being based on findings from focus groups with racially/ethnically diverse, symptomatic postmenopausal women. Items were refined after cognitive interview pretesting and field-tested among symptomatic postmenopausal women enrolled in a multiethnic cohort study in California. Exploratory factor analysis (SAS PROC VARCLUS) and confirmatory factor analysis evaluated factor structure and eliminated poorly fitting items. Additional evidence of construct validity was obtained via examination of correlations with other measures of related constructs. Internal consistency and test-retest reliability were assessed using Cronbach &agr; and correlation coefficients, respectively. ResultsFor the 745 postmenopausal women who completed the draft questionnaire, the mean (SD) age was 56.2 (8.5) years, and 66% of the respondents were racial/ethnic minorities. The refined questionnaire included four multi-item scales addressing symptom impact on (1) activities of daily living, (2) emotional well-being, (3) sexual functioning, and (4) self-concept and body image. The four-factor model provided good approximate fit (comparative fit index, 0.987; standardized root-mean-square residual, 0.038). Correlations with other measures of symptom bothersomeness, sexual function, depression, and anxiety conformed to hypotheses. Cronbach &agr; values ranged from 0.82 to 0.93. Intraclass coefficients ranged from 0.47 to 0.72. ConclusionsThe Day-to-Day Impact of Vaginal Aging questionnaire is a new multidimensional self-report measure designed to facilitate evaluation of the impact of vaginal symptoms on postmenopausal women of diverse backgrounds.
This paper references
10.1016/S0022-5347(05)00039-X
Differences in prevalence of urinary incontinence by race/ethnicity.
D. Thom (2006)
10.1080/10705519909540118
Cutoff criteria for fit indexes in covariance structure analysis : Conventional criteria versus new alternatives
Li-tze Hu (1999)
10.1177/0049124192021002005
Alternative Ways of Assessing Model Fit
M. Browne (1992)
10.1371/journal.pone.0048230
The Multidimensional Assessment of Interoceptive Awareness (MAIA)
W. Mehling (2012)
10.1023/A:1008884703919
The development of a quality of life instrument for use with post-menopausal women with urogenital atrophy in the UK and Sweden
S. McKenna (2004)
10.1891/1061-3749.9.2.151
Reliability and Validity Testing of the Revised 12-Item Short-Form Health Survey in Older Adults
B. Resnick (2001)
Corrections to test statistics and standard errors in covariance structure analysis.
A. Satorra (1994)
10.1016/S0029-7844(02)02369-4
Menopausal Symptoms in Older Women and the Effects of Treatment With Hormone Therapy
V. Barnabei (2002)
10.1097/00005650-199603000-00003
A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.
J. Ware (1996)
The North American Menopause Society. Unauthorized reproduction of this article is prohibited
© Copyright (2015)
New Interventions for Menopausal Symptoms Meeting Summary. Bethesda, MD: National Institutes of Health
N Santoro (2007)
Scientific Software International
K G Joreskog (2012)
10.1001/archinte.168.8.840
Persistent hot flushes in older postmenopausal women.
A. Huang (2008)
10.1111/j.1532-5415.2009.02353.x
Sexual function and aging in racially and ethnically diverse women.
Alison J. Huang (2009)
10.1037/0033-2909.107.2.238
Comparative fit indexes in structural models.
P. Bentler (1990)
10.1097/AOG.0b013e31816386ce
Factors Associated With Worsening and Improving Urinary Incontinence Across the Menopausal Transition
L. E. Waetjen (2008)
10.1080/009262300278597
The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function.
R. Rosen (2000)
The Hospital Anxiety and Depression Scale.
G. Huston (1987)
10.1016/J.MATURITAS.2004.06.019
Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative.
L. Pastore (2004)
10.1097/gme.0b013e3181acb9ed
Vaginal symptoms in postmenopausal women: self-reported severity, natural history, and risk factors
A. Huang (2010)
10.1097/GME.0b013e318282600b
The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women
E. Erekson (2013)
10.1067/MOB.2003.23
Are women with urogenital atrophy symptomatic?
G. Davila (2003)
10.1007/s11606-009-1135-1
The Day-to-Day Impact of Urogenital Aging: Perspectives from Racially/Ethnically Diverse Women
A. Huang (2009)
10.1016/j.juro.2009.01.046
Sexual function among overweight and obese women with urinary incontinence in a randomized controlled trial of an intensive behavioral weight loss intervention.
Alison J. Huang (2009)
New Interventions for Menopausal Symptoms Meeting Summary
N Santoro (2007)
10.1097/gme.0b013e318148b98b
The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status
P. Gupta (2008)
10.1016/S0029-7844(01)01508-3
Is Incontinence Associated With Menopause?
M. Sherburn (2001)
10.1177/1359105306065021
Depression and Body Image among Women with Polycystic Ovary Syndrome
M. Himelein (2006)



This paper is referenced by
10.1007/s41975-020-00135-2
„Genitourinary syndrome of menopause“ – vaginale Östrogene im Vergleich
Petra Stute (2020)
10.7257/1053-816X.2017.37.6.310
The Impact of Genitourinary Syndrome of Menopause On Quality of Life
Amy Hull (2017)
10.1111/jgs.14708
Aging, the Medical Subspecialties, and Career Development: Where We Were, Where We Are Going
A. Hurria (2017)
10.1080/14656566.2019.1574752
Pharmacotherapy for the treatment of vaginal atrophy
Gilbert G G Donders (2019)
10.1080/13697137.2018.1559806
Rationale and design for fractional microablative CO2 laser versus photothermal non-ablative erbium:YAG laser for the management of genitourinary syndrome of menopause: a non-inferiority, single-blind randomized controlled trial
Richard Foster Flint (2019)
10.1080/09513590.2016.1183627
Diagnosis and management of symptoms associated with vulvovaginal atrophy: expert opinion on behalf of the Italian VVA study group *
R. Nappi (2016)
10.1097/GME.0000000000001496
The European Vulvovaginal Epidemiological Survey (EVES): impact on sexual function of vulvovaginal atrophy of menopause.
Martire Particco (2020)
10.1097/GME.0000000000001390
Measurement properties of patient-reported outcome measures (PROMs) for women with genitourinary syndrome of menopause: a systematic review.
M. Gabes (2019)
10.1097/GME.0000000000000414
Vaginal health prescription: possible next step in the management of genitourinary syndrome of menopause.
G. Bachmann (2015)
10.1097/GME.0000000000001121
Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health
Stephanie S. Faubion (2018)
Managing postmenopausal dyspareunia : An update
Susan Hoff (2018)
10.1177/1203475417708165
A Dermatologist’s Approach to Genitourinary Syndrome of Menopause
Matthew Hum (2017)
10.1007/978-3-319-63540-8_23
GSM/VVA: Advances in Understanding and Management
Nick Panay (2018)
10.1093/pm/pnw306
Development and Feasibility of a Group-Based Therapeutic Yoga Program for Women with Chronic Pelvic Pain
A. Huang (2017)
10.1097/GME.0000000000001007
Shining the light on genitourinary syndrome of menopause in survivors of breast cancer.
Sheryl A Kingsberg (2017)
10.3389/fendo.2019.00561
Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women
R. Nappi (2019)
10.1097/gme.0000000000001416
A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
M. Paraiso (2019)
10.1097/GME.0000000000001148
The impact of genitourinary syndrome of menopause on well-being, functioning, and quality of life in postmenopausal women
E. Moral (2018)
10.1080/01443615.2019.1621824
The effect of vulvovaginal atrophy on women’s quality of life from an Italian cohort of the EVES study
R. Nappi (2019)
10.1016/j.jsxm.2019.10.010
Convergent-Divergent Validity and Correlates of the Day-to-Day Impact of Vaginal Aging Domain Scales in the MsFLASH Vaginal Health Trial.
Mary M Hunter (2019)
10.1016/J.YFPN.2018.12.002
Improving the Care of Women with Vulvovaginal Atrophy in Primary Care
Susan G. Wiers (2019)
10.5772/INTECHOPEN.74666
Ethical Considerations in Research and Medical Care of Menopause
Claudia Camelia Calzada Mendoza (2018)
10.1016/j.maturitas.2015.05.010
Low-dose 17-β-estradiol cream for vaginal atrophy in a cohort without prolapse: Serum levels and vaginal response including tissue biomarkers associated with tissue remodeling.
Jana D. Illston (2015)
10.1097/GME.0000000000001138
The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review
J. Simon (2018)
10.1164/rccm.201806-1198OC
Development and Preliminary Validation of the Lung Transplant Quality of Life (LT‐QOL) Survey
J. Singer (2019)
10.1097/GME.0000000000001260
The burden of vulvovaginal atrophy on women's daily living: implications on quality of life from a face-to-face real-life survey
R. Nappi (2018)
10.33667/2078-5631-2019-4-33(408)-38-43
Results of open multi‑centre comparative randomized study of efficiency and safety of application of three therapeutic schemes of vaginal capsules Triogynal for treatment of vaginal atrophy in postmenopausal women
V. E. Balan (2020)
10.1016/J.MATURITAS.2019.03.013
Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
N. Panay (2019)
10.1016/j.ajog.2019.12.270
Patient-Centered Change in the Day-to-Day Impact of Postmenopausal Vaginal Symptoms: Results from a Multicenter Randomized Trial.
C. Gibson (2020)
10.1080/13697137.2017.1319815
Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women
G P Siliquini (2017)
10.1097/GME.0000000000000482
Predictors of impact of vaginal symptoms in postmenopausal women
Mary M. Hunter (2016)
10.1080/13697137.2018.1527306
What should guide our patient management of vulvovaginal atrophy?
M. Shapiro (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar